The abstract is read at the publisher; the summary is JClub's.
Engineered Salmonella, Escherichia coli, Listeria, and Yersinia can be programmed to localize, sense cues, regulate activity in situ, and persist for controlled periods.
- Why it matters: Bacteria-based therapeutics are promising but need genetic control that preserves precision, safety, stability, and activity under clinical conditions while avoiding off-target behavior and evolutionary loss.
- What they did: The review synthesizes genetic design layers—chassis selection, attenuation and biocontainment, activity control, targeting and persistence—and discusses genotype-to-phenotype stability during manufacturing and in vivo use.
- The result: It outlines liabilities and emphasizes progress toward safe, clinically translatable chassis with integrated, bounded, durable behaviors, including candidates and programmed bacteria that deliver gene editing systems.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.